Phase II study of docetaxel and carboplatin as second-line treatment in NSCLC

Lung Cancer

Volumn 45, Issue 2, 2004, Pages 255-262

  Wachters, Floris M ^a   Van Putten, John W G ^b   Boezen, H Marike ^c   Groen, Harry J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Carboplatin; Carcinoma, non small cell lung; Clinical trial, phase II; Docetaxel; Second line chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; BLOOD TOXICITY; BONE MARROW; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG EFFICACY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL ASSESSMENT; GRANULOCYTOPENIA; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TOXICITY; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 3042747569     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.02.006     Document Type: Conference Paper

References (32)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer, a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
2. Cullen M.H., Billingham L.J., Woodroffe C.M., Chetyawardana A.D., Gower N.H., Joshi R., et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J. Clin. Oncol. 17:1999;3188-3194
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:2002;92-98
4. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
5. Belani C.P. Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol. 25:1998;10-14
6. Crino L., Mosconi A.M., Scagliotti G.V., Selvaggi G., Rinaldi M., Della G.M., et al. Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial. Semin Oncol. 25:1998;23-26
7. Sculier J.P., Lafitte J.J., Berghmans T., Thiriaux J., Licomte J., Efremidis A., et al. A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. Lung Cancer. 29:2000;67-73
8. Pronzato P., Landucci M., Vaira F., Vigani A., Bertelli G. Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res. 14:1994;1413-1415
9. Sculier J.P., Berghmans T., Lafitte J.J., Richez M., Recloux P., Van Cutsem O., et al. A phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung Cancer. 37:2002;73-77
10. Laack E., Dierlamm T., Knuffmann C., Popp J., Schmied B., Durk H., et al. Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer. 36:2002;303-307
11. Hainsworth J.D., Thompson D.S., Greco F.A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol. 13:1995;1609-1614
12. Fossella F.V., Lynch T., Shepherd F.A. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer. 38:2002;5-12
13. Fossella F.V., Lee J.S., Shin D.M., Calayag M., Huber M., Perez-Soler R., et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol. 13:1995;645-651
14. Gandara D.R., Vokes E., Green M., Bonomi P., Devore R., Comis R., et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol. 18:2000;131-135
15. Robinet G., Thomas P., Perol M., Vergnenegre A., Lena H., Taytard A., et al. Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy French Group of Pneumo-Cancerology. Rev Mal Respir. 17:2000;83-89
16. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based hemotherapy. J Clin Oncol. 18:2000;2095-2103
17. Fossella F.V., Devore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 18:2000;2354-2362
18. Lilenbaum R.C., Langenberg P., Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response toxicity, and survival. Cancer. 82:1998;116-126
19. Belani C.P., Einzig A., Bonomi P., Dobbs T., Capozzoli M.J., Earhart R., et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol. 11:2000;673-678
20. Zarogoulidis K., Kontakiotis T., Hatziapostolou P., Fachantidou E., Delis D., Goutsikas J., et al. A Phase II study of docetaxel and carboplatin in the treatment of non-small cell lung cancer. Lung Cancer. 32:2001;281-287
21. Giannakakis T., Kakolyris S., Theodoropoulos E., Kouroussis C., Michailakis E., Papadouris S., et al. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Anticancer Res. 22:2002;3743-3748
22. Millward M.J., Boyer M.J., Lehnert M., Clarke S., Rischin D., Goh B.C., et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol. 14:2003;449-454
23. Chatelut E., Canal P., Brunner V., Chevreau C., Pujol A., Boneu A., et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 87:1995;573-580
24. World Health Organisation. WHO Handbook for reporting results of cancer treatment. Geneva, Switzerland, 1979.
25. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 38:1982;143-151
26. Oka M., Fukuda M., Nagashima S., Fukuda M., Kinoshita A., Soda H., et al. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 48:2001;446-450
27. Georgoulias V.A. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer. 38:2002;61-66
28. Kakolyris S., Papadakis E., Tsiafaki X., Kalofonos C., Rapti A., Toubis M., et al. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer. 32:2001;179-187
29. Niho S., Kubota K., Goto K., Ohmatsu H., Matsumoto T., Kakinuma R., et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Cancer Chemother Pharmacol. 52:2003;19-24
30. Androulakis N., Kouroussis C., Kakolyris S., Tzannes S., Papadakis E., Papadimitriou C., et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol. 9:1998;1127-1130
31. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 21:2003;2237-2246
32. Hanna N.H., Shepherd F.A., Rosell R., Pereira J.R., De Marinis F., Fossella F., et al. A phase III study of pemetrexed vs. docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy. Proc Am Soc Clin Oncol. 22:2003;622